Pharma Clinical Trial Digitization—Companies to Action, 2019

Collision of Healthcare with Life Sciences IT Systems will Continue to Transform the Clinical Trials Market
Share this:
Published: 11 Apr 2019

Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-centric and efficient distributed settings. As the clinical trial industry transitions to biomarker-based, targeted therapeutics, it demands a pivotal shift in design focus: from one directed by researchers to one driven by the needs of patients and their caregivers. Frost & Sullivan observes that leading pharmaceutical companies, in particular, are aggressively moving toward the mixed approach of physical and remote clinical trial settings to improve patient engagement and justify the value of future personalized drugs. Furthermore, increasing demand for quality data and novel endpoints demands clinical trial data management solutions to shift from fragmented point solutions that sit in silos to integrated eClinical solutions that provide a single source of truth, optimizing the cost by eliminating duplicate data entry, reducing on-site verification and source data verification rate. This entails an evolving vendor ecosystem of modular cloud-based eClinical solutions with an intuitive user interface capable of integrating all possible study and eSource data to optimize clinical trial digital workflows and data management cost and time.



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..